54 studies on Semax curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,733 published Semax COA source records from third-party laboratories, covering 694 publicly attributable vendor identities. Across 1,570 records with positive numeric purity, the arithmetic mean is 99.44%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 29 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-14. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.00 | $5.00–$6.50 | $1.20 | 3 sources · 3 offers |
| 10 mg | $10.12 | $9.00–$12.00 | $1.01 | 4 sources · 4 offers |
| 30 mg | $16.00 | $16.00–$16.00 | $0.53 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-14. Aggregate calculated: 2026-10-18T15:38:11.858576+00:00. Calculation time is not a laboratory observation date.
Within that total, 544 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 30 | 99.31% | 0 of 23 (0.0%) 0 0% / not detected · 0 wrong compound · 7 unclassified | Reveal with Pro → | |
| #2 | 16 | 99.32% | 0 of 16 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 14 | 99.51% | 0 of 14 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120432 (99.36%) · #119431 (99.6%) · #120548 (99.25%) · #119233 (99.88%) · #120534 (99.39%) · #120490 (99.9%)
Developing advanced **magnetic shielding materials** is crucial for improving the accuracy and sensitivity of magnetic detection in diverse fields like biomedicine and fundamental physics. Multi-layer designs, especia…
A multi-layer magnetic shield combining Fe-based nanocrystalline and Co-based amorphous ribbons achieved **51.7 dB** shielding effectiveness, outperforming single-material designs.
This research represents a substantial advancement in the field of formal software verification, particularly for the widely used C language. The ability to formally verify software components with greater precision a…
This study provides strong preclinical evidence for Semax's potential as a therapeutic agent for stress-induced anxiety and depression. Given that Semax is a well-studied peptide already used clinically in some countr…
**Semax's bell-shaped dose-response curve is the critical practical constraint**: underdosing misses the efficacy window, and overdosing reverses it, making sloppy titration genuinely counterproductive rather than mer…
**Semax's superiority over PGP under ischemia** suggests the N-terminal portion of the molecule — beyond the shared PGP tripeptide — contributes critical neuroprotective properties that cannot be reduced to its C-end …
This research provides compelling evidence that simple proline-containing peptides can offer significant protection against stress-induced hypercoagulation, a critical factor in cardiovascular disease. The activation …
This research highlights a potentially significant role for semax as a novel therapeutic agent in managing and preventing stress-induced hypercoagulation. Given that chronic physiological and psychological stress are …
These findings are crucial as they suggest that Semax's nootropic and analgesic effects involve distinct mechanisms and potentially different brain regions. Understanding these route-dependent differences allows for o…
This research is significant because enhanced proteolytic stability is a critical factor for improving the pharmacokinetic profile and therapeutic efficacy of peptide-based drugs like Semax. By identifying specific N-…
This research highlights that Semax shows promise as a therapeutic agent for addressing behavioral and developmental deficits induced by early life stress, such as maternal deprivation. The ability of Semax to normali…
This research provides compelling evidence that nootropic drugs can effectively improve cognitive and emotional behaviors, particularly in individuals (or in this case, mouse strains) predisposed to higher anxiety and…
This research highlights potential therapeutic strategies for mitigating the devastating effects of focal brain ischemia, particularly in critical areas like the prefrontal cortex, which is vital for executive functio…
This research underscores Semax's significant potential as an antistress agent, specifically in protecting vital immune organs like the spleen from stress-induced damage. Its ability to reduce macrophage proliferation…
This review underscores the significant therapeutic potential of peptide bioregulators for age-related neurological conditions and cognitive decline. By consolidating evidence on both complex and short peptides, it pr…
The review demonstrated that neonatal injections of various pharmacological agents consistently led to detectable, long-term alterations in adult animals. These changes manifested across diverse domains, including aud…
The enhanced proteolytic stability of simple glyprolines is a critical finding for peptide drug design, particularly for developing therapeutics that require prolonged activity or specific routes of administration. Pe…
This research reveals a novel mechanism for Semax's neuroprotective action: metal chelation. For users, this suggests that Semax's benefits may be particularly pronounced in contexts of heavy metal exposure or suspect…
This research significantly reinforces the nootropic properties of Semax, demonstrating its capacity to both enhance learning in specific contexts and facilitate the recovery of learned behaviors following disruption.…
This research suggests that semax could serve as a valuable adjunctive therapy for managing the lipid metabolism disturbances commonly seen in psoriasis patients with metabolic syndrome. Correcting these lipid abnorma…
This research provides compelling evidence for the potential of semax to act as a therapeutic intervention against neurodevelopmental issues caused by early-life exposure to SSRIs like fluvoxamine. Given the increasin…
This study provides compelling evidence for the hepatoprotective potential of Semax in mitigating stress-induced liver damage and dysfunction. The peptide's ability to normalize liver enzyme activities and protein syn…
The findings suggest that Semax directly enhances the efficiency of glutamate release and alters the short-term dynamics of sensory synapses. For peptide users, this provides a potential mechanism for its reported noo…
This research highlights that while Semax possesses general antioxidant properties, its effects on liver enzyme markers under stress are highly nuanced and dose- and context-dependent. The finding that higher doses ca…
This review significantly advances our theoretical understanding of Semax's mechanism of action, identifying transthyretin (Ttr) as a potential key mediator in its neuroprotective effects. Unraveling this specific pat…
This study provides compelling evidence for the neuroprotective properties of Semax against heavy metal-induced cognitive impairment. Given the widespread environmental exposure to heavy metals and their significant i…
The findings demonstrate that the free N-terminal amino group of Semax is indispensable for its neuroprotective activity against copper-induced toxicity. For users, this implies that **acetylated Semax (Ac-Semax) is n…
Sympathetic overactivity is a well-established driver of adverse cardiac events and poor prognosis following myocardial infarction. The findings that Semax peptide can moderate this activation, prevent sympathetic ner…
This research suggests that **Semax's neuroprotective mechanism is primarily mediated through its potent modulation of the neuroimmune system**, rather than a direct neurotrophic effect. For users, this highlights tha…
This chemoreactome analysis provides a comprehensive molecular blueprint for mexidol, clarifying its diverse pharmacological actions beyond its known antioxidant properties. The identification of its potential as an a…
This review reinforces that the nervous and immune systems are not isolated; they are deeply interconnected, and interventions targeting one will predictably affect the other. For clinicians and individuals using immu…
Semax's ability to reduce excessive and potentially detrimental sympathetic innervation growth after MI is a highly significant finding, as dysregulated nerve growth can contribute to dangerous arrhythmias and further…
The findings suggest that **Semax could be a valuable adjunctive therapy to standard post-stroke rehabilitation protocols**. By boosting `BDNF` levels, Semax appears to enhance the underlying biological mechanisms of …
This research provides experimental substantiation for Semax's role as an immunomodulator, highlighting its potential to counteract the detrimental effects of stress on the immune system. Given that chronic stress is …
This study validates human IPSC-derived neurons as a powerful and relevant model for screening and quantifying the neuroprotective effects of compounds like Semax. For researchers and biohackers interested in neuropro…
This study highlights the potential of peptide drugs like deltalicin as novel therapeutic agents for managing diabetic dyslipidemia. The finding that deltalicin was more potent than existing treatments suggests it cou…
This research provides compelling evidence for a novel protective role of Semax against stress-induced alterations in gut microbiota, highlighting its potential as a therapeutic agent for maintaining gut health under …
This research highlights the complex and context-dependent role of ACTH4-7-PGP (Semax) in pain modulation, moving beyond a simplistic view of its effects. Understanding this dual action could pave the way for more tar…
The findings suggest a potential therapeutic role for Semax in mitigating the neurodevelopmental side effects associated with perinatal SSRI exposure. For individuals concerned about the long-term impact of in-utero o…
This research identifies Semax as a potent pharmacological activator of the `PGC-1α` pathway in the context of ischemic brain injury. For individuals exploring neuroprotective agents, this provides a specific mechanis…
This research provides a more granular understanding of Semax's mechanism of action in a neuroprotective context, specifically linking its benefits to the downregulation of a precise set of inflammatory genes. For ind…
This research reinforces the molecular basis for Semax's use in **ischemic stroke**, moving beyond genetic transcription to confirm its effects on functional protein expression. For individuals exploring nootropics or…
These findings provide crucial insights into the cellular targets and initial interaction dynamics of Semax within the brain, particularly highlighting its specific impact on hippocampal neurons. The observed increase…
Free, no account — handy when you're working with Semax.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account